For Immediate Release For Further Information Contact:
April 8, 2015 Thomas Toland
949-698-8485 mobile
SURGLINE UPDATE on Biologics and Allergy SLIT testing
WEST PALM BEACH, Fla., April 8, 2015 SurgLine International, Inc. (SGLN.PK)
SurgLine International, Inc. and its wholly owned subsidiary SurgLine Inc. is waiting for the manufacturer of its Sublingual Immunotherapy product to receive its final approval of labeling. The FDA has recently issued its intent to further evaluate biologics and labeling requirements. At this point, the Company has no definitive timeframe as to the FDA’s guidance and must wait for labeling guidance.
The Company has ceased to market its surgical implant products to hospitals and surgery centers due to a lack of interest in savings by its targeted customer base when compared to traditional legacy brands in spite of costing substantially more.
Although, hospitals and surgery centers say that they desire to save money while using the Company’s products, the physician acceptance and conversion to our generic products has been difficult to establish in any meaningful manner at this point in time.
The Company concludes that the legacy companies offer such historical acceptance with the physician community that is difficult to convert from these legacy products to a more cost effective product offering.
Forward Looking Statements
This update release may contain forward-looking statements, including information about management’s view of future expectations, plans and prospects for SurgLine International, Inc. (the "Company"). In particular, when used in the preceding discussion, the words "predicts", "believes", "expects", "intends", "seeks", "estimates", "plans", "anticipates", "concludes" and similar conditional expressions or future or conditional verbs such as "will", "may", "might", "should" "would" and "could" are intended to identify forward-looking statements. In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statements as bine expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included herein are made only as of the date hereof. The company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date of the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that re not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under item, "Risk Factors" of the Company’s annual Report on Form 10-K for the year ended July 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.
